This has been an important year for HIV research. There were five new approvals of new drugs or fixed dose combinations (FDCs), including the first in class monoclonal antibody, but not all drugs have been approved yet in both the US and the EU, and one, was only approved in China.
An i-Base report says this study reviews recently approved and pipeline HIV drugs and is linked to the upcoming i-Base Fit for Purpose review on treatment optimisation – due to be launched in 22 July 2018 before AIDS 2018.
[link url="http://i-base.info/htb/34488"]i-Base report[/link]
[link url="http://i-base.info/htb/wp-content/uploads/2018/07/PIPELINE-2018-full-version.pdf"]Full i-Base version (PDF)[/link]